SCHEMBL25138972

SCHEMBL25138972

CC(C)c1cc(-c2ccc3ccccc3c2)cc(C(C)C)c1CC(N)=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGER3 P43115 2/20 0.43
▸ EPHX1 P07099 1/20 0.42
▸ SLC1A3 P43003 1/20 0.40
▸ SLC1A2 P43004 1/20 0.40
▸ SLC1A1 P43005 1/20 0.40
▸ ICMT O60725 3/20 0.40
▸ ACMSD Q8TDX5 1/20 0.40
▸ ESR1 P03372 1/20 0.40
▸ ESR2 Q92731 1/20 0.40
▸ ALOX5 P09917 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ S1PR4 O95977 1/20 0.39
▸ S1PR5 Q9H228 1/20 0.39
▸ AKR1C3 P42330 1/20 0.39
▸ AKR1C2 P52895 1/20 0.39
▸ HSD17B1 P14061 1/20 0.38
▸ HSD17B2 P37059 1/20 0.38
▸ SLC6A2 P23975 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30791048 0.87 ACMSD (0.44) SLC1A3SLC1A2SLC1A1ACMSDESR1
SCHEMBL20681207 0.87 ACMSD (0.44) SLC1A3SLC1A2SLC1A1ACMSDESR1
SCHEMBL25139030 0.85 HSP90AA1 (0.40) —
SCHEMBL20938321 0.81 MCL1 (0.39) ICMTCA1CA2
SCHEMBL20681162 0.80 MTNR1A (0.38) PTGER3ACMSDAKR1C3AKR1C2SLC6A2
SCHEMBL25067147 0.80 AKR1C3 (0.38) PTGER3EPHX1SLC1A3SLC1A2SLC1A1
SCHEMBL30791033 0.80 MTNR1A (0.38) PTGER3ACMSDAKR1C3AKR1C2SLC6A2
SCHEMBL25138977 0.78 IKBKB (0.43) ACMSD
SCHEMBL25139155 0.78 ESR1 (0.43) ACMSDESR1ESR2ALOX5CA1
SCHEMBL25139100 0.77 PPARG (0.37) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3658538-B1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2023-04-19 — — EP disclosed
Send feedback